Ocugen reports 31% lesion growth reduction at 12 months in Phase 2 ArMaDa trial of OCU410 for geographic atrophy

OCUGEN INC

OCUGEN INC

OCGN

0.00
  • Ocugen reported topline 12-month results from the Phase 2 ArMaDa trial of OCU410 (AAV5-RORA), a single subretinal gene therapy being studied for geographic atrophy secondary to dry age-related macular degeneration.
  • In the medium-dose group, the study showed a 31% reduction in geographic atrophy lesion growth versus control at 12 months (p<0.05).
  • Safety findings reported to date included no OCU410-related serious adverse events and no cases of endophthalmitis, retinal detachment, vasculitis, choroidal neovascularization, or ischemic optic neuropathy.
  • The Phase 2 trial randomized 51 patients 1:1:1 to medium dose, high dose, or no treatment control.
  • Ocugen said it plans to initiate a Phase 3 registrational trial in the third quarter of 2026 with up to 300 subjects.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocugen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603240745PRIMZONEFULLFEED9677457) on March 24, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.